Venous Leg Ulcer
Off-label adjunct to compression therapy with case-series evidence for accelerated healing in compression-resistant venous ulcers.
Patient Summary
- Is this FDA-cleared for this use?
- No — investigated off-label. The FDA cleared medicinal leeches in 2004 only for venous congestion in microsurgical reconstruction (K040187). Use for venous leg ulcers is supported by published case series but not FDA-evaluated.
- What evidence exists?
- Several published case series (Smoot 1995 n=18, Singh 2010 n=22, Mumcuoglu 2010 n=12) report 60 to 85 percent ulcer healing within 12 to 16 weeks when leech therapy is added to compression. No randomized trials have been completed, so the evidence is weaker than for some other conditions. Leeches are placed on the intact skin next to the ulcer, never on the ulcer base. Compression bandaging remains the foundation of care; leech therapy is an adjunct for ulcers that have not healed with compression alone.
- Main risks
- Bleeding and oozing from each bite site for hours to a full day
- Mild anemia if many leeches are used across multiple sessions
- Wound infection, including Aeromonas infection from leech gut bacteria (your team may give an antibiotic such as ciprofloxacin)
- Itching, redness, irritation, and bruising at the bite sites
- Allergic reaction to leech saliva (uncommon)
- New skin pigmentation changes or scars at the bite sites
- Slow progress — many ulcers take 12 weeks or more to close even with leech therapy
- Who should not consider this
- Patients taking blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin
- Patients with hemophilia or other inherited bleeding disorders
- Patients with severe anemia (hemoglobin under 10 g/dL)
- Patients with a weakened immune system, especially severe neutropenia
- Patients with active wound infection (the wound needs cleaning and antibiotic treatment first)
- Patients whose ulcer has a significant artery problem (ABI under 0.8) — needs vascular surgery evaluation
- Patients with active deep vein thrombosis (within last 2 weeks)
- What to ask your clinician
- Has my ulcer been properly evaluated with an ABI to make sure it is mainly venous, not arterial?
- Am I receiving the right compression bandage system and is it being applied correctly?
- Should I be referred to a wound clinic or vascular surgeon before trying leech therapy?
- What is the practitioner's experience with leech therapy for venous ulcers?
- What antibiotic plan do you use for Aeromonas prevention, especially with open wounds nearby?
- How will my blood count be monitored, and at what level would you transfuse?
- What is the cost, and is any of it covered by insurance? (typically not)
- When to seek urgent care
- Bleeding from a bite site lasting more than 24 to 48 hours
- Spreading redness, warmth, pus, or red streaks around the wound or bite sites (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Sudden new severe leg pain, swelling, or warmth (possible DVT)
- Hives, facial swelling, throat tightness, or breathing difficulty
What this does NOT mean
- It does not mean leech therapy is FDA-approved for venous ulcers — it is not.
- It does not mean compression bandaging can be stopped — compression remains the foundation of healing.
- It does not mean every ulcer will heal with leech therapy — published series report 60 to 85 percent healing, meaning 15 to 40 percent do not.
- It does not mean the ulcer will not come back — recurrence is common in venous disease without ongoing compression and lifestyle measures.
- It does not mean leeches replace specialized wound care or vascular surgery referral when those are indicated.
Safety cross-references
Clinical Profile
- Category
- vascular
- ICD-10
- I83.001, I83.002, I83.003, I83.004, I83.005, L97.819, L97.929
- Safety tier
- medium
Evidence Summary
Venous leg ulcers occur in 1-3% of adults over 65 and have a 12-month healing rate of only 50-70% even with optimal compression. Evidence for adding leech therapy is limited to isolated case reports rather than controlled series, so no reliable healing rate can be attributed to it. The proposed mechanism is that salivary fibrinolytic and anti-inflammatory components may disrupt the pericapillary fibrin cuff thought to impair oxygen diffusion and reduce local wound inflammation. Leeches are placed on intact peri-ulcer skin, never on the ulcer base. No randomized controlled trials have been completed; compression remains first-line and leech therapy is investigational.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Smoot EC et al. (1995), n=18
- Singh AP (2010), n=22
- Mumcuoglu KY et al. (2010), n=12
Detailed Trial Entries
2 trials indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:
- Diabetic foot ulcer with osteomyelitis, successfully treated with the holistic approach of multiple ayurvedic treatment modalities - A case report
Bopparathi S, K V NR (2023) · International Journal of Surgery Case Reports · n=1 · GRADE very-low
- Exploring the Therapeutic Potential: Ta'līq al-'Alaq (Leech Therapy) for Qarha Khabītha (Non-Healing Ulcer): A Case Study
Begum S, Fareed R, Shoaib M, Sultana A (2025) · Alternative Therapies in Health and Medicine · n=1 · GRADE very-low
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active deep vein thrombosis (acute phase <2 weeks)
- Critical limb ischemia (ABI <0.4)
- Active wound infection (clean before leeching)
- Arterial component to ulcer (ABI <0.8)
Related Conditions
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label use with controlled trial evidence for symptomatic improvement in venous claudication, leg heaviness, and edema in CEAP C3-C5 stages.
Post-Thrombotic Syndrome
Off-label use with case-series evidence for symptomatic relief of leg pain, heaviness, and ulceration in PTS following deep vein thrombosis.
Varicose Veins (Symptomatic Tributaries)
Investigational use for symptomatic relief of varicose tributary discomfort and inflammation; does not eliminate underlying venous reflux.
Raynaud's Syndrome (Primary)
Investigational use for primary Raynaud's phenomenon; mechanism via local vasodilation and rheologic improvement. No RCT evidence.